Physician profile
Thomas Bobst
NPI 1346277126
$3,580.81
in general payments reported to CMS, 2019-2025
12 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,952 · 2020: $116 · 2021: $335 · 2022: $619 · 2023: $90.59 · 2024: $281 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,872.00 | 2019-2025 | Hydrus Microstent, Precision7 |
| Ivantis, INC | $472.84 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $435.27 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $127.35 | 2021-2022 | |
| Allergan, INC. | $126.54 | 2022 | |
| Bausch & Lomb Americas INC. | $123.20 | 2024 | Miebo, Xiidra |
| Shire North American Group INC | $121.01 | 2019 | |
| Oyster Point Pharma, INC. | $98.49 | 2022 | |
| Heru, INC. | $88.42 | 2022 | |
| Abb Con-Cise Optical Group LLC | $65.69 | 2019 | |
| Coopervision INC. | $31.45 | 2021-2025 | Myday Contact Lens |
| Kala Pharmaceuticals, INC. | $18.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bobst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.